Check for updates

Recent advances and discoveries in the mechanisms and functions of CAR T cells

Rebecca C. Larson[1,2] *and Marcela V. Maus*[1,2]✉

Abstract | This Review discusses the major advances and changes made over the past 3 years to our understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the field has gained insight into how various molecular modules of the CAR influence signalling and function. We report on mechanisms of toxicity and resistance as well as novel engineering and pharmaceutical interventions to overcome these challenges. Looking forward, we discuss new targets and indications for CAR T cell therapy expected to reach the clinic in the next 1–2 years. We also consider some new studies that have implications for the future of CAR T cell therapies, including changes to manufacturing, allogeneic products and drug-regulatable CAR T cells.

Camelid antibodies
Antibodies generated from Camelidae mammals, which have two identical heavy chains and, compared with typical antibodies, are much smaller (15 kDa compared with 150 kDa) and lack a light chain.

[1]*Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.*

[2]*Immunology Program, Harvard Medical School, Boston, MA, USA.*

✉*e-mail: mvmaus@mgh.harvard.edu*

https://doi.org/10.1038/s41568-020-00323-z

After two decades of fine-tuning T cell engineering, the tremendous clinical success of chimeric antigen receptor (CAR) T cells in patients with leukaemia and lymphoma has led to an exponential growth in research within the field. The US Food and Drug Administration (FDA) approval of CAR T cells in 2017 catapulted the field into an era of fast-paced and innovative research. Here, we discuss what the field has learnt since this milestone and how it will affect the future of CAR T cell therapy. We start with a brief review of the basic CAR design and discuss what has been discovered in the past few years about each component's effect on the signalling and function of the engineered cell. Interestingly, it now seems that each component of the CAR matters for determining its function, with even single amino acid changes resulting in alterations in the signalling threshold for antigen binding, exhaustion and persistence. We also describe the toxicities that appear to be a class effect of CD19 CAR T cells — cytokine release syndrome (CRS) and neurotoxicity — with updated findings from advanced clinical trials. Until very recently, preclinical CAR T cell research was limited by a lack of adequate animal models, but recent advances in more humanized approaches have enabled systematic testing of potential interventions and also elucidated mechanisms underlying toxicities. We next review our current understanding of resistance to CAR T cells and how it can be overcome with innovative CAR T cell design. Finally, we discuss a selection of promising new targets and indications as well as manufacturing innovations that will likely have a major effect on the future of CAR T cell therapy.

CAR engineering

The first generation of CARs consisted of an extracellular antigen-recognizing single-chain variable fragment (scFv) developed from an antibody sequence fused to a transmembrane region and the intracellular signalling domain derived from the CD3ζ molecule of the endogenous T cell receptor (TCR)[1–4]. However, these CAR T cells had little efficacy in clinical trials owing to failed expansion and persistence[5]. Second-generation CARs include a co-stimulatory domain, derived from either CD28 or 4-1BB and located between the transmembrane and CD3 signalling domains[6,7]. The first patients with B cell leukaemia treated with second-generation CD19-targeted CAR T cells had profound and durable responses[8–10]. As a result, CAR T cell therapy revolutionized the treatment of haematological malignancies and was FDA approved in 2017 owing to its efficacy against $CD19^+$ tumours[11,12] (see TABLE 1 for results from major published clinical trials).

CAR parts and assembly. The extracellular portion of a CAR is typically derived from the variable light (V_L) and variable heavy (V_H) regions of an antibody (scFv) against the tumour target of interest (FIG. 1). The linker between these two domains is commonly derived from repeated glycine and serine residues, but other linker molecules have also been used (that is, the Whitlow linker[13]). To overcome the structural and aggregation issues associated with scFvs, some CARs have instead been designed to use the single-domain V_{HH} of camelid antibodies, natural ligands or artificial protein-binding constructs[14–16]. The hinge (also called

Table 1 | **Major published trials of CAR T cell therapy**

Target antigen	Disease	CAR	Clinical trial identifier	Sponsor	Number of patients analysed	Median age (years)	Response	Patients with CRS (%)	Patients with neurotoxicity (%)
CD19	B-ALL (paediatric)[a]	Tisagenlecleucel; 4-1BB co-stimulation; CTL019	NCT02435849 (REFS[53,199])	Novartis Pharmaceuticals	75	11	6-month relapse-free survival rate of 80%	77	40
CD19	Relapsed or refractory DLBCL[a]	Axicabtagene ciloleucel; CD28 co-stimulation; KTE-X19	NCT02348216 ZUMA-1 (REFS[52,200,201])	Kite Pharma (a Gilead Sciences company)	101	58	83% objective response; 58% complete response	93	67
CD19	Refractory B cell lymphomas[a]	Tisagenlecleucel; 4-1BB co-stimulation; CTL019	NCT02030834 (REFS[202,203])	UPenn	28	58.5	64% overall response; 43% complete remission	57	39
CD19	Mantle cell lymphoma[a]	Axicabtagene ciloleucel; CD28 co-stimulation; KTE-X19	NCT02601313 ZUMA-2 (REFS[204,205])	Kite Pharma	68	65	93% objective response rate; 67% complete response	91	63
CD19	B-ALL	CD28 co-stimulation	NCT01044069 (REFS[206,207])	MSKCC	53	44	83% complete remission; median overall survival 12.9 months	85	44
CD22	Relapsed or refractory pre-B-ALL	4-1BB co-stimulation	NCT02315612 (REFS[106,208])	NCI	21	19	73% complete remission treated with higher dose	76	Unreported
BCMA	Relapsed or refractory multiple myeloma	Idecaptagene cicleucel; 4-1BB co-stimulation; bb2121	NCT02658929 (REFS[137,209])	Celgene	33	60	85% objective response rate; 45% complete response rate	76	42
BCMA	Multiple myeloma	4-1BB co-stimulation	NCT02546167 (REFS[138,210])	UPenn	25	58	48% overall response rate	88	32

B-ALL, B cell acute lymphoblastic leukaemia; BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; DLBCL, diffuse large B cell lymphoma; MSKCC, Memorial Sloan Kettering Cancer Center; NCI, National Cancer Institute; UPenn, University of Pennsylvania. [a]US Food and Drug Administration (FDA) approval.

the spacer region) links the antigen-recognizing extracellular domain to the transmembrane region. Some flexibility of this hinge is needed in order to allow the scFv domain to bind its cognate antigen. Various hinge regions have been used in CAR designs, including domains developed from CD28 and CD8 (REF.[17]). The transmembrane portion of the CAR spans the cell membrane lipid bilayer and often is also derived from CD28 or CD8. It is thought that this domain can influence molecular interactions between CARs, forming homodimers or trimers based on the endogenous transmembrane association of the original protein[18,19]. All current FDA-approved CAR T cell products are a second-generation design with either a CD28 or 4-1BB co-stimulatory domain[11,12]. In addition to CD28 (REF.[20]) and 4-1BB (REF.[21]), other common co-stimulatory domains include OX40 (REF.[22]), CD27 (REF.[23]) and inducible T cell co-stimulator (ICOS)[24]. If two co-stimulation domains are used in one construct, this is considered a third-generation CAR[22]. The CD3ζ cytoplasmic domain is the most distal intracellular part of the CAR. This molecule contains three immunoreceptor tyrosine-based activation motifs (ITAMs) that signal upon phosphorylation[25]. Some investigators have termed CARs with enhanced T cell function 'fourth-generation' CARs, particularly when they produce an additional protein molecule, such as cytokines, or possess additional receptors, such as co-stimulatory ligands. These are also referred to as TRUCKs (T cells redirected for universal cytokine killing) or armoured CARs[26,27].

CAR T cells are activated upon scFv recognition of antigen, which causes clustering and immobilization of the CAR molecules. Phosphorylation of the ITAM domains on the CD3ζ chain initiates signalling through the tyrosine kinase ζ-associated protein of 70 kDa (ZAP70), similar to TCR signalling[28]. This unleashes a T cell effector response including proliferation, release of cytokines, metabolic alterations and cytotoxicity. CAR T cells are thought to mainly exert their cytotoxic function through secretion of granzyme and perforin, but there are some data to suggest that death receptors are also utilized, based on activation of downstream molecules such as BH3-interacting domain death agonist (BID) and FAS-associated death domain protein (FADD)[29–31]. Signalling from the co-stimulatory domain is dependent on the specific function of the domain chosen and can be modulated by specific mutations in canonical sequences[32,33].

Graft-versus-host disease
(GvHD). A condition that can occur after allogeneic transplant owing to donor cells recognizing the host as foreign, resulting in donor cell attack of the host body.

Leukapheresis
A procedure in which white blood cells are separated from the blood and the remaining cells are returned to the circulation.

Artificial antigen-presenting cells
(Artificial APCs). Synthetic versions of APCs that activate immune cells; in the context of chimeric antigen receptor (CAR) T cells, artificial APCs are engineered with T cell receptor (TCR) stimulation and co-stimulatory molecules to expand T cells ex vivo.

CAR manufacturing. FDA-approved CAR T cells are derived from the patient's own cells (autologous), which circumvents issues of allogeneic rejection or graft-versus-host disease (GvHD) but requires individual bespoke manufacturing. Of note, CARs do contain foreign sequences and can be rejected, although this effect is partly mitigated by the use of the antimetabolite fludarabine in the preparative chemotherapy regimen, to facilitate lymphodepletion[34]. Autologous CAR T cell manufacturing typically begins with leukapheresis of the patient, although some investigators have used non-separated whole peripheral blood[35]. The T cells are then activated ex vivo with stimulation and co-stimulation, respectively, through their TCR (CD3) and a chosen ligand (often CD28) in the presence of a cytokine cocktail. Stimulating antibodies can be added in soluble form, chemically conjugated to beads or expressed on artificial antigen-presenting cells (APCs)[36,37]. The T cells are typically grown in the presence of interleukin-2 (IL-2), but other cytokines including IL-7 and IL-15 are also used to manipulate the overall T cell phenotype with varying degrees of success[38–40]. After activation, the CAR construct is introduced into the T cells, typically by viral or non-viral vectors. Both retroviral and lentiviral vectors have been described as safe and effective, and both integrate randomly into the host T cell genome[41,42]. Electroporation of cells with non-viral vectors is a method of gene transfer with much lower costs, but safety and efficacy are still being assessed[43]. Some CAR T cell manufacturing now includes gene editing by CRISPR–Cas9 or transcription activator-like effector nuclease (TALENs)[44,45], which can be used in combination with an adeno-associated viral vector to target integration of the CAR into a particular locus. Finally, CAR T cells are grown on the scale of days in bioreactors and then delivered back to patients for infusion. Typically, CAR T cells are given as a single dose, or sometimes split over 2 or 3 days; regardless, this is still substantially different from most cancer drugs, which are given either daily or every 3–4 weeks until disease progression.



Fig. 1 | **Schematic of a basic second-generation CAR T cell.** The extracellular portion of the chimeric antigen receptor (CAR) molecule is typically generated from a monoclonal antibody against the target. The variable heavy (V_H) and variable light (V_L) chains, also known as the single-chain variable fragment (scFv), from the antibody sequence are connected by a linker to form the antigen-specific region of the CAR molecule. The hinge or spacer region anchors the scFv to the transmembrane region that traverses the cell membrane. Intracellularly, the co-stimulatory domain and CD3ζ chain signal once the scFv portion of the CAR recognizes and binds tumour antigen. Co-stimulatory signals are dependent on the co-stimulation domain used: CD28 is dependent on PI3K, whereas 4-1BB requires tumour necrosis factor (TNF) receptor-associated factors (TRAFs) and nuclear factor-κB (NF-κB). The CD3ζ chain contains three immunoreceptor tyrosine-based activation motif (ITAM) domains that, upon phosphorylation (P), signal through ζ-associated protein of 70 kDa (ZAP70). Downstream signalling leads to T cell effector functions including release of perforin and granzyme, leading to cell death of the target tumour cell. IL-2, interleukin 2.

CAR signalling and exhaustion

What makes the 'best' CAR T cell remains a controversial question. A convoluting factor in clinical trials is that every clinically approved CAR T cell product is different, because it is made from the T cells of a specific patient. Clinical data have identified that responses correlate with expansion of CAR T cells, persistence and a memory phenotype[46], so avoiding or delaying T cell exhaustion is considered to be a key goal.

Proliferative capacity. In clinical studies with the CD19-targeted CAR, detectable CAR T cell expansion in patient blood is correlated with the response[46]. Further evidence that sustained CAR T cell proliferation is beneficial was revealed by a very particular case study. A patient with chronic lymphocytic leukaemia (CLL) treated with two infusions of CAR T cell therapy initially showed tumour progression in their bone marrow. However, 2 months after the second infusion, CAR T cell expansion peaked in the blood with corresponding tumour regression eventually leading to a complete response. Upon further investigation of the CAR T cell expansion, it was determined that a single CAR T cell clone had expanded, leading to the much delayed antitumour response. The cell had biallelic disruption of the tet methylcytosine dioxygenase 2 (*TET2*) gene owing to lentiviral integration in one allele and a hypomorphic mutation in the other. The *TET2* double knockdown caused a change in the epigenetic landscape leading to increased proliferation and a more central memory-like phenotype of the cells, resulting in a robust antitumour response[47]. A genome-wide CRISPR screen in human primary T cells identified additional genes that may have a similar effect if deleted: suppressor of cytokine signalling 1 (*SOCS1*), transcription elongation factor B polypeptide 2 (*TCEB2*; also known as *ELOB*), RAS GTPase-activating protein 2 (*RASA2*) and *CBLB* (encoding an E3 ubiquitin ligase). Disruption of these genes showed enhancement in both proliferation and in vitro cytotoxicity towards tumour cells[48]. Further investigation into viral integration sites in patient CAR T cells showed that responders have enriched insertional

Transcription activator-like effector nucleases (TALENs). DNA-binding domains fused to non-specific DNA-cleaving nucleases to target a specific sequence for gene alteration.

Hypomorphic mutation
An altered gene resulting in lower expression and/or activity of the gene product.

mutagenesis in genes encoding proteins in cell signalling and chromatin modification pathways that promote proliferation. Based on these data, investigators were able to create a model where clinical outcome could be predicted based on the vector integration site[49]. These studies suggest that CAR T cells with modifications in genes encoding proteins that influence proliferation may result in a more efficacious cell product, but this will need to be balanced against concerns over potential oncogenic transformation.

CAR T cells with increased proliferation and survival capacity have proven beneficial in various disease contexts. $CD8^+$ T cells in patients with CLL have impaired T cell activation characterized by reduced glucose uptake after stimulation[50]. These impaired T cell responses are thought to be responsible for the lower response rate to CAR T cells observed in patients with CLL compared with other B cell malignancies; interestingly, patients with CLL who did have complete responses to CAR T cells were noted to have enhanced mitochondrial biogenesis in their $CD8^+$ T cells, which correlated with the expansion and persistence of CAR T cells[50]. In multiple myeloma, it has been observed that T cells from patients with early onset disease have better fitness for CAR T cell manufacturing and potentially better efficacy compared with those from patients with relapsed or refractory disease[51].

Differences in co-stimulation. CAR T cells with different co-stimulatory domains in their CARs have been noted to have different dynamics, with the presence of a 4-1BB co-stimulation domain conferring slower expansion and longer persistence compared with the presence of a CD28 co-stimulation domain, which leads to rapid expansion but less durability[52,53]. The molecular basis for this difference is not well understood, but previous studies have shown that CD28-based CAR T cells exhibit a more effector-like memory phenotype and have an enhanced glycolytic metabolism, whereas 4-1BB-based CAR T cells have a more central memory phenotype and rely on fatty acid metabolism[54–56]. Furthermore, it has been shown that cytotoxic $CD8^+$ lymphocytes receiving 4-1BB co-stimulation have superior proliferation, ex vivo expansion into memory $CD8^+$ T cells and enhanced cytolytic activity compared with $CD8^+$ T cells with CD28 co-stimulation[57]. More recent investigation into the difference between these two co-stimulation pathways shows that 4-1BB CARs, but not CD28 CARs, activate non-canonical nuclear factor-κB (NF-κB) signalling after ligand engagement. Interfering with this signalling through overexpression of a dominant-negative mutant — the carboxy terminus of NF-κB-inducing kinase (NIK; also known as MAP3K14), which is a widely used strategy to block non-canonical NF-κB signalling — reduces the proliferation and survival of 4-1BB-based CAR T cells owing to an increase in expression of the apoptotic signalling molecule BIM (also known as BCL2L11)[58]. In addition to NF-κB, 4-1BB signalling is also reliant on tumour necrosis factor (TNF) receptor-associated factors (TRAFs), which affect CAR T cell viability, expansion and cytotoxicity in part due to regulating NF-κB. Overexpression of TRAFs in 4-1BB-based CAR T cells enhances their function[59]. Another comparison made between 4-1BB versus CD28 used a phosphorylated protein approach to show that the effector-like phenotype of CD28-based CAR T cells correlated with fast activation and larger changes in the magnitude of protein phosphorylation. The intensity of this signal is partly owing to constitutive association of the tyrosine kinase LCK with the CD28 intracellular CAR domain. By contrast, RNA sequencing shows that the lower degree of phosphorylation in activated 4-1BB-based CAR T cells is associated with higher expression of memory-associated genes relative to CD28-based CAR T cells[33,60]. Additionally, Li et al.[61] have shown that the persistence and memory phenotype of 4-1BB-based CAR T cells can be further enhanced by limiting the ubiquitylation of the CAR (by mutating ubiquitin-targeted lysine residues in the CAR molecule). This increased recycling of the CAR molecule, as opposed to its degradation, enhances oxidative phosphorylation due to elevated endosomal 4-1BB signalling[61].

Conversely, when trying to design CARs for $CD4^+CD25^+$ regulatory T cells (T_{reg} cells), which function to protect tissue, the co-stimulation that elicits a desirable phenotype is reversed. CAR T_{reg} cells benefit from a CD28 domain that retains their suppressive activity in vivo against a desired target. This differs from 4-1BB-based CAR T_{reg} cells, which can become increasingly cytotoxic due to the effects of the co-stimulation[62].

Various co-stimulatory domains beyond CD28 and 4-1BB have been used in combination with CD3ζ signalling for CAR T cell therapy. Recent work shows that ICOS increases persistence of CAR T cells[63]. Additionally, ICOS in combination with 4-1BB co-stimulation as a third-generation CAR design shows superior efficacy in solid tumour mouse models over 4-1BB-based second-generation CARs. Interestingly, the membrane-proximal intracellular co-stimulatory domain has the dominant effect in third-generation CAR T cells[63].

Tuning CAR signalling. In addition to augmenting the proliferative capacity of CAR T cells, limiting their exhaustion is also beneficial to the antitumour response. T cell research has shown that strong T cell activation drives exhaustion[64,65], so several efforts have been made to tune CAR signalling to alleviate exhaustion. Antigen and CAR molecule density both have a large impact on efficacy — low expression of either contributes to a limited antitumour response[66]. Tuning CAR signalling with different linkers[67,68], hinge and transmembrane domains[69–71], co-stimulation[69], ITAMs[25] and promoters (to moderate CAR molecule expression)[72] can all influence CAR functionality depending on the amount of tumour antigen present (TABLE 2).

Primarily, alterations in the spacing regions between the V_L and V_H regions and the transmembrane domain affect the flexibility of the CAR construct, therefore determining its ability to access and bind its target antigen epitope[73,74]. More recently, Singh et al.[67] showed that a CAR based on the same scFv targeting CD22 but with different linker lengths (20 amino acids versus 5 amino acids) had different clinical responses. Despite

Table 2 | **Tuning CAR signalling with each component**

CAR component	Potential changes	Potential influences in function
Linker	Length[67,68]	Dimerization leading to differences in tonic signalling
		Potency
Hinge and transmembrane	Length[73,74,77,78], type (for example, CD8α, CD28)[69–71]	Immunological synapse formation
		Cytokine production and AICD
		Efficacy with low-density target antigen expression
Co-stimulation	Type (for example, CD28, 4-1BB, ICOS)[33,57–59,62,63]	Initial expansion
		Persistence
		Durability of response
		Memory phenotype and cell fate
ITAMs	Number of functional domains[25,69]	Memory phenotype and cell fate
		Efficacy with low-density target antigen expression
Promoter	Synthetic or endogenous[72]	CAR expression (number of molecules per cell)
		CAR internalization
		Differences in tonic signalling
		Memory phenotype and cell fate

AICD, activation-induced cell death; CAR, chimeric antigen receptor; ICOS, inducible T cell co-stimulator; ITAM, immunoreceptor tyrosine-based activation motif.

similar binding affinities, the CAR with a longer linker formed monomers in solution whereas the shortened version formed homodimers, which was associated with increased tonic signalling. The shorter linker CAR demonstrated superior antitumour function both in vitro and in vivo, leading to a new clinical trial using a shortened-linker CD22 CAR (NCT03620058 (REF.[75]) and NCT02650414 (REF.[76]))[67]. Qin et al.[68] also explored the effects of linkers in the design of bispecific CAR T cells targeting CD19 and CD22, and showed that linker length had a profound effect on CAR construct potency.

In addition to linker length, it is known that the hinge length needs to be optimized. How distal (shorter hinges) or proximal (longer hinges) the target antigen epitope is to the target cell membrane determines the formation of an immunological synapse[73,74,77,78]. More recently, hinge and transmembrane domains have also been shown to have a much more important role than initially expected, and much work is now going on to optimize CAR constructs based on the proper combination of these clearly more than structural components[70]. For example, in a direct comparison of CARs bearing a CD8α hinge and transmembrane domain or a CD28 hinge and transmembrane domain, CD8α-based CARs had lower levels of both cytokine production and activation-induced cell death[71]. Furthermore, Majzner et al.[69] have also recently shown that differences in co-stimulation molecules, once believed to be the main drivers of differences in CAR T cell phenotypes, can be manipulated to behave more similarly in the context of low levels of the tumour antigen by changing the hinge–transmembrane region of the CAR T cell construct.

It has also been demonstrated that manipulating the ITAM domains of the CAR construct alters signalling. The activation of CD28-based CAR T cells can be calibrated using ITAM mutants to change the binding affinity of ZAP70. Through these mutations, CAR T cells can be directed to different fates, enabling a CD28-based CAR T cell with mutations in ITAM1 and ITAM2 domains to persist with long-lived memory but retain effective antitumour function[25]. Engineering additional ITAM domains into 4-1BB-based CAR T cells enables them to recognize low antigen density-expressing target cells (typically a threshold only reached by CD28-based CAR T cells)[69].

Another approach is to mimic the signalling of the endogenous TCR, which has evolved to fine-tune endogenous T cell responses. Using CRISPR–Cas9, CAR integration can be targeted to the endogenous TCRα chain (TRAC) locus, resulting in expression controlled by the endogenous T cell promoter. This results in uniform CAR expression, but, more importantly, enhances T cell potency by averting tonic CAR signalling. CARs are internalized and re-expressed upon exposure to antigen, which delays T cell exhaustion and terminal differentiation to an effector T cell fate[72]. In a novel design, the scFv of an antibody has been combined with the γ and δ chains of the TCR to serve as the effector domains. These so-called antibody–TCR (AbTCR) cells retain the cytotoxic activity of CD28-based or 4-1BB-based CAR T cells but with less cytokine release resulting in less exhaustion[79]. Additionally, two groups recently published that insertion of the CD3ε molecule into the CAR enhances antitumour function by tuning CAR signalling with less cytokine production and longer persistence[80,81].

Emerging mechanisms of toxicity

The two hallmark clinical toxicities associated with CAR T cell therapy are CRS and neurotoxicity, and neither was predicted by animal modelling before clinical translation. CRS typically manifests in patients within the first week of CAR T cell therapy as fever, hypotension and respiratory insufficiency with high serum cytokine levels[82,83] (FIG. 2). Neurotoxicity is exhibited as temporary working memory loss, delirium, seizures and, rarely, acute cerebral oedema[84]. Both CRS and neurotoxicity are attributed to rapid activation and expansion of the T cells that secrete cytokines. The current understanding is that cytokines secreted by the CAR T cells and/or ligand–receptor interactions activate additional immune cells of the myeloid compartment, which in turn release more cytokines to create a loop of activating inflammation called a cytokine storm. Naturally occurring adrenaline in patients has also been shown to contribute to this self-amplifying production loop[85,86]. Although neurotoxicity has been clinically associated with CRS, the mechanisms involved appear to be different[87].

In some cases, neurotoxicity or CRS-associated multi-organ failure can be lethal. A high tumour burden and higher CAR T cell expansion have been correlated with higher grades of CRS[88]. Overall, CARs with a 4-1BB co-stimulation domain seem to cause less neurotoxicity and CRS than those with a CD28 domain[84]. In a study of 53 adult patients who received CD28-based CD19-targeted CAR T cells for the treatment of acute lymphoblastic leukaemia (ALL), 62% of the patients developed neurotoxicity, of which 67%

Tonic signalling
Ligand-independent constitutive signalling of a chimeric antigen receptor (CAR).

Activation-induced cell death
Programmed cell death caused by repeated stimulation of T cells that serves as a negative regulator of activation.



Fig. 2 | **Current molecular understanding and therapeutic intervention of CAR T cell-induced cytokine release syndrome and neurotoxicity.** Upon recognition of tumour antigen, the antitumour response activated downstream in chimeric antigen receptor (CAR) T cells leads to activation of innate immune cells owing to secretion of inflammatory cytokines such as granulocyte–macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor (TNF) and interferon-γ (IFNγ). This leads to a self-amplifying inflammatory activation loop in macrophages causing release of interleukin-1 (IL-1) and IL-6. Therapeutic intervention at various stages of this response can mitigate neurotoxicity and cytokine release syndrome (CRS). Therapeutics targeting GM-CSF (lenzilumab), the IL-6 receptor (tocilizumab) and the IL-1 receptor (anakinra) have been used for this purpose clinically. The tyrosine kinase inhibitor dasatinib affects T cell signalling to reduce CRS, and metyrosine inhibits macrophage inflammatory activation to achieve a similar effect.

was considered severe. Of the patients with severe neurotoxicity, 72% developed seizures, although these effects were transient[89]. In a similar study with 133 patients treated with 4-1BB-based CD19-targeted CAR T cells for ALL, 40% had a neurologic toxicity, with 8% of those patients experiencing seizures. In this case, most patients with high-grade neurotoxicity were involved in dose escalation later determined to be above the maximum tolerated dose[87]. Severe neurotoxicity in patients has been correlated with high levels of pro-inflammatory cytokines (IL-6, IL-8, CC-chemokine ligand 2 (CCL2) and CXC-chemokine ligand 10 (CXCL10)) in the cerebrospinal fluid (CSF)[89]. Evidence of blood–CSF barrier disruption correlates with the neurotoxicity grade, but the white blood cell count or CAR T cell count in the CSF does not[89]. Despite these observations, the mechanisms of neurotoxicity are currently unknown. However, we speculate that the increase in pro-inflammatory cytokines may activate endothelial cells in the brain vasculature, which leads to areas of increased permeability and capillary leak (known as vasogenic oedema) that manifest as focal oedema and neurotoxicity[87]. Another possible explanation suggested by a recent study is that brain mural cells express CD19 and that on-target CAR T cell activity against these cells results in neurotoxicity[90]. Clinically, the main treatment to overcome CRS is to break the feedback loop of cytokines through treatment with an IL-6 receptor monoclonal antibody, tocilizumab. Corticosteroids are often also used in combination with tocilizumab to reduce inflammation and vasogenic oedema in the brain. Yet neither of these interventions appears to block CAR T cell expansion in patients[88].

One of the challenges in designing new strategies to prevent or mitigate CRS is the set of limitations inherent in mouse modelling. The NOD–SCID–IL-2 receptor-γ null (NSG) mice typically used as preclinical models for CAR T cell therapy carry mutations that severely affect their immune compartment, including myeloid cells. However, the advantage of NSG mice is that human tumour cells and human T cells can be engrafted more efficiently than with other strains. In an attempt to better model human CRS, researchers have turned to other mouse strains, animal species or humanized mouse models. Giavridis et al.[91] developed a mouse model of CRS using SCID-beige mice that, similar to human CRS, develops 2–3 days after CAR T cell injection. These mice have a less impaired IL-1 response to interferon-γ (IFNγ) priming compared with NSG mice. In their model, 75% of these mice die due to CRS within 48 h. Interestingly, the CAR T cell cytokines themselves were not driving the CRS, although this could, in part, be due to the reliance of the model on cross-reactivity between human T cell-produced cytokines and mouse myeloid cell receptors. Despite limited cross-reactivity, mouse CRS was driven by production of mouse IL-6, IL-1 and nitric oxide produced by macrophages activated by the human CAR T cells[91]. In another example of an advanced model, Taraseviciute et al.[92] developed a rhesus macaque model of neurotoxicity in which CD20 CAR T cells caused a cascade of immune activation leading to atypically high levels of pro-inflammatory cytokines and chemokines in the CSF and infiltration of CAR^+ and CAR^- T cells into the brain parenchyma leading to encephalitis. The animals also exhibited symptoms characteristic of CRS, including fever and elevated C-reactive protein (CRP) levels[92]. Another group utilized the human CD19 transgene in mice to show increased levels of cytokines compared with the lack of CRS observed using mouse CD19. Furthermore, antibody-mediated neutralization of IL-6 or IFNγ in this model alleviated T cell-induced weight loss[93]. Another potential animal model utilizes a triple transgenic NSG (SGM3) mouse, which expresses human stem cell factor, granulocyte–macrophage colony-stimulating factor (GM-CSF) and IL-3 to mimic the innate immune component of CRS involvement. However, this model still relies on some mouse cytokines as part of the cytokine response, most importantly IL-6 (REF.[86]). In an effort to improve this CRS model to better mimic the human clinical phenomena, sublethally irradiated newborn SGM3 mice can be injected intrahepatically with human haematopoietic stem and progenitor cells. This more rapidly reconstitutes haematopoiesis and results in the production of human B cells, monocytes and T cells compared with non-transgenic NSG mice. As proof of principle of the effectiveness of this more advanced model, characterized

Maximum tolerated dose
The highest dose of treatment that does not cause intolerable side effects.

Suicide switches
Genetically encoded molecules included in a chimeric antigen receptor (CAR) vector that can be targeted to induce CAR T cell death.

by high fever and elevated human IL-6 levels, it was shown that tocilizumab can prevent CRS but does not protect against meningeal inflammation leading to lethal neurotoxicity[94].

Additional interventions to manage toxicity beyond IL-6 receptor blockade are under investigation, both in preclinical models and in clinical trials. Inhibiting GM-CSF signalling, either through monoclonal antibody neutralization (lenzilumab) or by genetically altering the CAR T cells to knock out GM-CSF, can limit CRS and neuroinflammation[95]. Giavridis et al.[91] and Norelli et al.[94] have demonstrated that disruption of the IL-1 pathway with anakinra, an IL-1 receptor antagonist, mitigates both CRS and lethal neurotoxicity in mice. Anakinra is now being tested clinically to prevent neurotoxicity in CAR T cell-treated patients[96]. In addition to cytokine intervention, others have shown that pharmacological blockade of catecholamine with metyrosine can protect mice from the lethal complications of CRS[86]. Other groups have sought to control CAR T cell toxicity not through addressing the toxicity itself, but by controlling the CAR T cell load and potency with the use of dasatinib, an FDA-approved tyrosine kinase inhibitor. Dasatinib limits CAR T cell signalling by preventing LCK phosphorylation and nuclear factor of activated T cells (NFAT) induction after CAR T cell engagement[97]. Unlike suicide switches that would irreversibly affect CAR T cell efficacy[98], dasatinib suppresses CAR T cell activation and function without killing the cells. This could be implemented in a clinical setting when early symptoms of CRS arise, whereby CAR T cells could be transiently turned off using dasatinib to prevent further cytokine secretion[97,99].

Mechanisms of resistance

One of the common mechanisms associated with relapse after CAR T cell therapy is loss of antigen (FIG. 3). Flow cytometry analysis of B cell acute lymphoblastic leukaemia (B-ALL) cells from patients with relapsed or refractory B-ALL that had relapsed after 4-1BB-based



Fig. 3 | **Antigen-dependent and antigen-independent resistance.** Resistance to chimeric antigen receptor (CAR) T cell therapy can be categorized according to the context of antigen loss or retention. Antigen loss is most commonly due to mutations in the gene encoding the antigen itself. However, there have been cases of antigen loss due to accidental transduction of a tumour cell leading to 'CAR masking' of the tumour antigen, resulting in relapse. In addition, reduced levels of tumour antigen can result in relapse and may be owing to trogocytosis, in which CAR molecules on T cells remove tumour antigen from the surface, internalize it and begin expressing the tumour antigen themselves. Antigen-independent resistance is due to exhausted T cells. This can result from a suboptimal infusion product with a terminal effector phenotype, loss of death receptor signalling on tumour cells making them resistant to CAR T cell killing, or an immunosuppressive tumour microenvironment due to $CD4^+CD25^+$ regulatory T cells (T_{reg} cells) and myeloid-derived suppressor cells (MDSCs) and their respective soluble factors. BID, BH3-interacting domain death agonist; FADD, FAS-associated death domain protein; IL-10, interleukin-10; PGE_2, prostaglandin E_2; TGFβ, transforming growth factor-β; TRAIL2, tumour necrosis factor-related apoptosis-inducing ligand 2.

Trogocytosis
A process where lymphocytes extract ligands from antigen-presenting cells and express them on their own surface.

CD19-targeted CAR T cell therapy showed that 12 of the 17 patients had progressed with CD19-negative disease. Sequencing of the genomes of the B-ALL cells revealed that all 12 patients had mutations in CD19 making the molecule unrecognizable to CAR T cells[100]. Selective pressure to mutate CD19 is the most common mechanism of antigen loss, and many patients who are relapsing are now screened to determine whether CD19 is still present. Although the most common, mutagenesis of CD19 is not the only documented mechanism of antigen loss. Ruella et al.[101] reported a patient with B-ALL who relapsed 9 months after receiving CD19 CAR T cell therapy. Quantitative PCR determined that the patient still had CAR sequences in blood cells but this did not correlate with an expansion of CAR T cells by flow cytometry, which instead showed an expansion of CD19-negative leukaemic cells. Further investigation revealed that the tumour cells had originated from one leukaemic B cell that had been transduced with CAR during manufacturing. The CAR molecule 'masked' CD19 on the surface of the cell, preventing it from being recognized by CAR T cells[101]. This is considered to be a rare event but has serious implications for the safety of manufacturing. In addition to complete loss of CD19, a third mechanism of antigen loss has been reported by Hamieh et al.[102], which explains how antigen-low tumour escape can occur. Through a process called trogocytosis, CARs remove target antigen from tumour cells and internalize it, leading to decreased antigen density on tumour cells. This affects both CD28-based and 4-1BB-based CAR T cells, but with differential consequences because CD28-based CARs are less sensitive to decreases in antigen density[102].

Antigen loss explains some relapses, but not all patients who relapse have antigen-negative disease[103], suggesting that there may be additional factors leading to resistance, such as exhaustion of CAR T cells. A study of responders and non-responders (with primary resistance) to CD19-targeted CAR T cells in CLL revealed that T cells in infusion products had a more effector-like signature, including differentiation, glycolysis, exhaustion and apoptosis, in patients who were non-responders. By contrast, T cells in infusion products from patients who responded had upregulation of IL-6 and signal transducer and activator of transcription 3 (STAT3) signatures. An elevated frequency of memory-like T cells ($CD27^+CD45RO^-CD8^+$) prior to CAR T cell generation is also associated with sustained remission[46]. Whole genome-wide loss-of-function screens in ALL cell lines have identified impaired death receptor pathways as another mechanism of resistance to CD19-targeted CAR therapy. Loss of FADD, BID and tumour necrosis factor-related apoptosis-inducing ligand 2 (TRAIL2) in tumour cells renders them more resistant to CD19-targeted CAR T cell efficacy, both in vitro and in vivo, owing to lower cytotoxicity and proliferation of the CARs[29,30]. Furthermore, prolonged CAR stimulation by ALL cells lacking one of these death receptor molecules leads to T cell exhaustion[29,46].

Most of the experience in the field with CAR T cell therapy is in the setting of haematological malignancies, where the tumour microenvironment (TME) is thought to play much less of a role in response. However, as the field looks beyond CD19-targeted CAR T cells to solid tumours, a suppressive TME may also generate resistance to CAR T cell treatment. This is especially a concern with difficult to penetrate, highly immunosuppressive solid malignancies such as glioblastoma or pancreatic cancer. The lack of chemokines to attract the CAR T cells, an abnormal vasculature and extracellular matrix-producing cancer-associated fibroblasts can all make it difficult for CAR T cells to even traffic to the tumour. Once there, immunosuppressive cells and cytokines, including T_{reg} cells, myeloid-derived suppressor cells, transforming growth factor-β (TGFβ), IL-6, IL-10 and prostaglandin E_2 (PGE_2), inhibit CAR T cell proliferation and effector functions[104].

Overcoming resistance

Overcoming antigen loss. The most straightforward approach to preventing antigen escape is the development of CARs targeting other antigens, which could be used in series or in tandem. CAR T cells targeting CD20 and CD22 are in clinical development both in stand-alone and tandem scFv formats[105,106]. Another group has leveraged natural CD40–CD40 ligand (CD40L) cytotoxicity: through constitutive expression of CD40L, CAR T cells are able to engage CD40 both on $CD40^+$ tumour cells (directly engaging cytotoxicity) and also on tumour-adjacent APCs. Activated APCs then increase expression of co-stimulatory molecules and major histocompatibility complex (MHC) class II to recruit additional effector cells, such as endogenous T cells that can assist in tumour killing through their endogenous TCRs, even in the absence of tumour cell expression of the CAR antigen[107]. Another approach is to increase antigen expression on the target cells. Small-molecule γ-secretase inhibitors have been shown to increase B cell maturation protein (BCMA; also known as TNFRSF17) expression on myeloma cells by impairing cleavage of surface-expressed BCMA. This combination treatment with BCMA-targeted CAR T cells is now in a clinical trial (NCT03502577 (REF.[108])). Similarly, bryostatin 1 has been shown to upregulate CD22 and increases the efficacy of CD22-targeted CAR T cell therapy in preclinical models, although the mechanism of this CD22 upregulation remains to be elucidated[109]. In addition, scFv affinity can be tuned to the expression pattern of the tumour. Liu et al.[110] have shown, when comparing similarly designed CARs against the same antigen but with various affinities, that higher affinity scFvs are able to recognize antigen at low expression levels even undetectable by flow cytometry.

Overcoming exhaustion. The field of cancer immunotherapy was revolutionized with the development of immune checkpoint blockade. PD1 is upregulated on T cells upon activation and binds its natural ligand (PDL1) to dampen the T cell response, both in terms of proliferation and effector function[111]. Studies have shown that blockade of the PD1–PDL1 axis can be leveraged to overcome T cell inhibition owing to PDL1 expression in tumours[112]. This translated into FDA approval of monoclonal antibodies against PD1 and

PDL1, which have since had great clinical success in oncology[113]. What has been learnt with immune checkpoint blockade in overcoming T cell exhaustion is now being applied to CAR T cells, including combinatorial treatment, autocrine secretion of anti-immune checkpoint molecules from CAR T cells and genetic perturbation of immune checkpoint genes in CAR T cells themselves. For example, Cherkassky et al.[114] have shown that CAR T cell combinatorial treatment with a PD1 antibody can restore CD28-based CAR T cell effector function in mouse models where they typically become exhausted. There are now many ongoing clinical trials evaluating the effects of combinatorial immune checkpoint blockade (targeting either PD1 or PDL1) with CD19-targeted CAR T cells (NCT02650999 (REF.[115]), NCT02706405 (REF.[116]), NCT02926833 (REF.[117]) and NCT03310619 (REF.[118])). Early results suggest that combinatorial treatment is safe and has a low toxicity profile. One case report has even demonstrated the benefit of combinatorial treatment: a patient with diffuse large B cell lymphoma who progressed post CD19-targeted CAR T cell therapy received anti-PD1 therapy at day 26 post CAR T cell transfusion. By day 45, significant tumour regression was observed, and by 3 weeks post PD1 blockade, the patient was able to return to work[119]. To avoid the need for two separate therapeutics, researchers have also tested CAR T cell-intrinsic secretion of antibodies against immune checkpoint molecules including anti-PD1 and anti-PDL1 in preclinical models[120,121]. Similar benefits to those achieved with combinatorial treatments were observed, including prolonging T cell function and limiting exhaustion. The additional benefit of local secretion of antibodies against immune checkpoint molecules is the potential to limit systemic toxicities[122]. Another approach is to engineer the CAR T cells to be resistant to PDL1. One study showed that exhaustion can be limited by transducing CAR T cells with a PD1 dominant-negative receptor to act as a sink to minimize PD1 signalling through the endogenous receptor[114]. An alternative method is to knock out the gene encoding PD1 in CAR T cells using CRISPR–Cas9. This improves antitumour immunity in vitro and within in vivo models in the presence of $PDL1^+$ tumours[123]. This method of genetic knockout has also been shown to be tolerated clinically with PD1 knockout T cells persisting in patients for up to 9 months[45].

Additional approaches not directly targeting immune checkpoints have also been utilized to overcome exhaustion. Expression of a constitutively signalling IL-7 receptor along with a CAR has the benefit of augmenting the CAR T cells after antigen exposure but avoids stimulating bystander cells (unlike cytokine-secreting CAR T cells). Specifically, the co-expression of this receptor with a CAR increases T cell proliferation, persistence and antitumour response without T cell dysfunction[124]. An alternative approach to limit exhaustion has been investigated in a mouse model of CAR tonic signalling. Exhaustion is associated with increased accessibility of activator protein 1 (AP1) transcription factor motifs, which leads to terminal differentiation of T cells. Overexpression of the canonical AP1 factor JUN combats the exhaustion, resulting in increased functional capacity and improved antitumour potency of the CAR T cells[125].

Overcoming the immunosuppressive tumour microenvironment. Innovative approaches to increase trafficking and limit suppression by anti-inflammatory cytokines and cells in the TME are also in development. One strategy is to increase the CAR T cell response through secretion of pro-inflammatory soluble factors. Overexpression of IL-7 and CCL19 in CAR T cells, which are required for formation of the T cell zone in lymphoid organs, increases infiltration of pro-inflammatory dendritic cells and T cells into solid tumour tissues and enhances tumour regression in mouse models[126]. Armoured CAR constructs overexpressing pro-inflammatory cytokines such as IL-12 and IL-18 have also been shown to activate more pro-inflammatory endogenous immune cells and enhance the antitumour response[127,128]. Alternatively, CARs engineered to express the IL-12β p40 subunit produce IL-23 upon T cell activation, which activates STAT3 signalling to promote proliferation. These CARs have superior efficacy in xenograft and syngeneic solid tumour mouse models. In addition, they have fewer side effects compared with IL-18-producing CARs, which may be due to reduced activation of bystander cells as IL-23 works in a predominantly autocrine manner[129].

Another strategy is to redirect or circumvent the suppressive TME. In prostate cancer, transduction of a dominant-negative TGFβ receptor (TGFβR) as a second transgene in the same vector as a prostate-specific membrane antigen (PSMA)-targeted CAR acts as a sink for the high localized levels of TGFβ in the tumour to limit its immunosuppressive effects[130]. This particular CAR construct is now in a phase I clinical trial (NCT03089203)[131]. Similarly, CRIPSR–Cas9-mediated knockout in CAR T cells of the endogenous TGFβRII led to CAR T cells that exhibited increased efficacy, less conversion to T_{reg} cells and less exhaustion in xenograft solid tumour models[132]. Another approach to overcoming T_{reg} cell-mediated immunosuppression is to alter the activity of the T_{reg} cells themselves. This idea stemmed from a CAR T cell clinical trial in glioblastoma targeting the epidermal growth factor receptor class III variant (EGFRvIII), which showed high intratumoural T_{reg} cell infiltration post CAR T cell infusion[133]. In a follow-up study, researchers developed an EGFR-bispecific T cell engager (BiTE) that is secreted by EGFRvIII-targeted CAR T cells and redirects conventional T cells and T_{reg} cells to exert cytotoxic function against the tumour[134]. This is a novel use of CAR T cells to co-opt immunosuppressive cells in the TME to promote an antitumour response. In a similar approach, an oncolytic adenovirus is used to deliver genetically encoded BiTEs to tumour cells in combination with CAR T cell therapy. Two solid tumour models of different cancer types, pancreatic and colon, show significant improvement to CAR T cell efficacy when treated in combination with the oncolytic virus BiTE[135]. Another group has generated an enhanced antitumour response by utilizing vaccination of amphiphilic CAR T ligands in combination with CAR T cell therapy. The strategy relies

Bispecific T cell engager
(BiTE). An artificial bispecific antibody made up of two single-chain variable fragments (scFvs) — one that recognizes a specific antigen and the other that binds CD3 on T cells, eliciting an activation response.

Amphiphilic
A description of a molecule containing both hydrophobic and hydrophilic regions.

on the injected amphiphilic ligands trafficking to lymph nodes and presenting to APCs to prime CAR T cells, leading to massive expansion[136].

Promising new targets and indications

Multiple myeloma. The leading target for CAR T cell therapy in multiple myeloma is BCMA (NCT02658929 (REF.[137]), NCT02546167 (REF.[138])). However, as is seen with CD19-negative relapse following treatment with CD19-targeted CAR T cells, BCMA-negative relapse can occur[139,140]. Two groups have suggested alternative, ligand-based CAR T cells that target both BCMA and another molecule expressed on multiple myeloma cells, transmembrane activator and CAML interactor (TACI; also known as TNFRSF13B). These CARs are based on a truncated form of the molecule a proliferation-inducing ligand (APRIL), which binds surface BCMA and TACI and is typically secreted by myeloid cells in the bone marrow. Lee et al.[14] used a single truncated (to prevent cleavable secretion and amino-terminal interactions with proteoglycans) APRIL molecule in a third-generation design with CD28 and OX40 co-stimulatory domains. This design was used in the clinical trial AUTO2 (NCT03287804 (REF.[141])) but was subsequently terminated due to a lack of preliminary efficacy. Schmidts et al.[19] designed a second-generation CAR with 4-1BB co-stimulation based on three repeated truncated APRIL molecules to mimic the trimeric soluble secreted form of the protein, which binds surface BCMA and TACI to promote myeloma growth. In multiple myeloma xenograft models, the trimeric form shows increased efficacy over the single APRIL CAR design[14,19].

Smith et al.[142] have identified an additional target for multiple myeloma, G protein-coupled receptor, class C group 5 member D (GPRC5D), which has an expression pattern on CD138$^+$ multiple myeloma cells independent of BCMA expression. Using a phage display system to generate scFvs, the authors screened 42 constructs using a Nur77 reporter system (Nur77 is an early indicator of TCR signalling) to identify an optimal second-generation CAR based on spacer length and low tonic signalling. In normal tissues, the GPRC5D protein is only expressed in the hair follicle[142]. To address concerns of on-target toxicity, Smith et al. used both mouse and non-human primate cynomolgus monkey models to show that there was a lack of alopecia when GPRC5D was targeted. GPRC5D-targeted CAR T cells were able to clear mice with a mixture of BCMA-positive and BCMA-negative multiple myeloma cells, whereas mice treated with BCMA-targeted CAR T cells succumbed to the disease[142]. Several other targets are also in development for multiple myeloma, including CD38, CD138 and SLAM family member 7 (SLAMF7)[143].

Solid tumours: pan cancer. A major concern in the field of CAR T cell therapy is its applicability beyond haematological malignancies. Many factors contribute to the hurdle of making an efficacious CAR T cell for solid tumours, including, but not limited to, a lack of tumour-specific antigens and an immunosuppressive TME. Many leaders in the field believe there are fewer than a dozen feasible CAR T cell targets beyond CD19, and identifying targets that have high, homogeneous expression in the tumour but not in healthy tissue (to limit on-target, off-tumour toxicity) has proven difficult.

The B7-H3 (also known as CD276) immune checkpoint molecule has been a popular immunotherapy target over the past few years, with a few promising clinical trials targeting the molecule with monoclonal antibodies (NCT02982941 (REFS[144,145]), NCT02381314 (REFS[146,147]), NCT03406949 (REFS[148,149]), NCT02628535 (REFS[150,151]) and NCT03729596 (REFS[152,153])). However, one of the main concerns with bringing forward a CAR T cell product targeting B7-H3 is on-target toxicity owing to low expression on normal tissue[154]. Using an antibody that has been found to only recognize high levels of B7-H3, Majzner et al.[154] designed a CAR T cell based on this specific scFv in an attempt to limit on-target toxicity of healthy tissues with low-level B7-H3 expression. They showed that in the context of high antigen density, which is true of several paediatric cancers including medulloblastoma, osteosarcoma and Ewing sarcoma, B7-H3-targeted CAR T cells were efficacious in vitro and in vivo. However, when antigen density is low, the B7-H3-targeted CAR T cells have much lower activity, suggesting that there may be a therapeutic window for an efficacious, non-toxic B7-H3-targeted CAR T cell therapy in the clinic[154].

He et al.[155] have designed so-called 237CART cells that can recognize multiple cancer-specific antigens. The 237CART cells are based on an antibody initially developed to recognize Tn-glycosylated podoplanin (Tn-PDPN). The basis of the tumour-specific recognition by 237CART cells is the result of loss-of-function mutations in *COSMC*, which encodes a molecular chaperone thought to be required for expression of active T-synthase, the only enzyme that galactosylates the Tn antigen during mucin type O-glycan biosynthesis. This differential pattern in Tn galactosylation, which results from COSMC mutation, has been shown to occur in ovarian cancer, leukaemia, breast cancer, sarcoma and neuroblastoma. The 237CAR T cell is of particular interest due to this pan-cancer recognition. In addition, He et al.[155] have shown that 237CART cells can recognize many Tn glycopeptides, not just Tn-PDPN. This is promising for 237CART cell therapy effectiveness as antigen escape may be avoided.

CAR T cells targeting mesothelin have been pursued in recent years for various indications, including pancreatic, lung and ovarian cancers. Preclinical models were promising, and several clinical trials are currently ongoing[156]. Initial results suggest that mesothelin-targeted CAR T cells are safe and have evidence of antitumour activity, which is promising for the future of CAR T cells for solid tumours[157,158]. Additional clinical studies are evaluating whether the mesothelin-targeted CAR T cell therapy can be enhanced with combination immune checkpoint blockade to augment the T cell response[157]. Recently, early phase I results (NCT03907852 (REF.[159])) were announced using a mesothelin-targeted T cell receptor fusion construct (TRuC)-based CAR. The scFv of this CAR is fused to TCR subunits and lacks the traditional co-stimulatory

Transposons
Genetic segments that can be translocated in the genome from one location to another by a DNA transposase.

domain. These CARs retain their cytotoxicity but have lower cytokine release and higher efficacy than traditional CAR T cells[160].

Solid tumours: brain. Brain tumours have remained relatively unresponsive to the wave of immunotherapies that have had incredible success and generated responses in other cancer types. However, there is potential for CAR T cell therapy to be used to treat brain tumours owing to the unique niche of the brain — unlike large molecules that frequently have difficulty gaining access to brain tumours because of the blood–brain barrier, T cells and T cell therapy can infiltrate the brain after intravenous transfusion[133]. The initial clinical trials of CAR T cell therapy against glioblastoma have targeted EGFRvIII, IL-13 receptor α2 (IL-13Rα2) and HER2 (also known as ERBB2), unfortunately with little efficacy likely owing to loss of the target antigen[133,161,162].

In an effort to overcome the heterogeneity of target antigen expression often found with glioblastoma, Wang et al.[163] have designed a CAR T cell based on a chlorotoxin (CLTX) peptide that has potent antitumour activity even in the absence of other glioblastoma-associated antigens. Flow cytometry staining of patient-derived glioblastoma cells for CLTX peptide revealed high and homogeneous expression of an unknown surface ligand compared with the heterogeneous expression of IL-13Rα2 and HER2. Their study shows that the efficacy of CLTX peptide-targeted CAR T cells is dependent on surface expression of metalloproteinase 2 (suggesting that the unknown antigen epitope is reliant on this proteinase to be recognized by the CAR T cell) and is non-toxic to normal tissues including peripheral blood mononuclear cells, induced pluripotent stem cells and an immortalized fetal brain-derived neural stem cell line. This research suggests that targeting the CLTX peptide with CAR T cell therapy could be promising as it may not have the same issues with antigen heterogeneity that has been observed with previous targets[163].

Disialoganglioside GD2-targeted CAR T cells targeting neuroblastoma have been previously well tolerated in clinical trials[164]. Mount et al.[165] have additionally suggested that GD2-targeted CAR T cells may be efficacious in diffuse midline gliomas with mutated histone H3 K27M (H3-K27M), which are a universally fatal paediatric cancer. Although the group demonstrated efficacy in patient-derived orthotopic xenograft models, they also observed peritumoural neuroinflammation, which led to lethal hydrocephalus in some animals. This study suggests that, with a cautious approach and aggressive neurointensive care management, GD2 CAR T cell therapy may be beneficial for H3-K27M$^+$ diffuse midline gliomas[165]. Recently, a new clinical trial (NCT03294954 (REF.[166])) has been initiated using Vα24-invariant natural killer T (NKT) cells transduced with an IL-15-expressing CAR targeting GD2. Interim analysis showed that the GD2-targeted CAR-NKT cells were well tolerated in three patients. One patient achieved an objective response with regressing bone metastatic lesions[167].

Bosse et al.[168] used an RNA sequencing-based pipeline to identify a novel target, a cell surface heparan sulfate proteoglycan GPC2, for neuroblastoma. GPC2 is highly expressed on neuroblastoma tissue, but not on normal paediatric tissues. Using an antibody–drug conjugate based on the cytotoxic capacity of pyrrolobenzodiazepine (PBD), Bosse et al.[168] showed reduced tumour growth by targeting GPC2 in a patient-derived xenograft model of neuroblastoma. It is possible that GPC2 may prove to be an efficacious CAR T cell target as well.

Manufacturing innovations

Gene transfer. A limitation of genetically reprogrammed T cell therapeutics is the use of viral vectors that have expensive and long production times for clinical use[169]. In addition, viral vectors have limited size constraints for the length of DNA that can be encoded (approximately 4 kb for adeno-associated viruses, 8.5 kb for adenoviruses and 10 kb for lentiviral vectors). Transposons have been explored over the past decade as a non-viral means of generating CAR T cells, as this method of gene transfer is more economical than viral-based methods. The Sleeping Beauty transposon-based system has been used to create CD19-targeted CAR T cells to treat patients with lymphoma and leukaemia who have relapsed following allogeneic haematopoietic stem cell transplants (NCT00968760 (REF.[170]), NCT01497184 (REF.[171]) and NCT03389035 (REF.[172]))[43,173]. Similarly, the piggyBac transposon system has been used over the past several years as another method to generate CAR T cells. One biotechnology company currently has two clinical trials ongoing using piggyBac-based CAR T cells[174,175]. Roth et al.[176] have developed a new non-viral method for delivering DNA sequences (>1 kb) to specific sites in the genome of primary human T cells using electroporation of CRISPR–Cas9 and double-stranded DNA. Using this method, a transgenic, cancer-specific TCR was introduced into the TCRα locus resulting in TCR-engineered T cells able to produce an antitumour response both in vitro and in vivo[176]. Further improvement of their design involves simultaneous orthotopic replacement of the endogenous TCRα and β locus, which avoids the mispairing of the endogenous and transgenic TCR chains (which can compete in typical transgenic TCR manufacture). As a result, they are able to recreate near-physiological T cell function[177]. However, it should be noted that, currently, this technique is still limited for large genetic loads (such as a large CAR construct), particularly for clinical use. In addition to changes in how genetic material is delivered, improved manufacturing of CAR T cells also involves how T cells are cultured ex vivo[40]. Groups have worked to determine the proper cocktail of cytokines for optimal growth conditions, and now others have joined the effort and introduced mimetic cytokines that may further enhance the production process[178].

Improving the effector cell type. Current manufacturing efforts use heterogeneous T cells from a patient (with the exception of CD4$^+$ T cell and CD8$^+$ T cell separation in some cases). However, there is evidence to suggest that some subsets of T cells may be more efficacious than others. Clinical trials have been conducted using central memory T cells for manufacturing CD28-based

CD19-targeted CAR T cells (NCT01318317 (REF.[179]) and NCT01815749 (REF.[180])). Initial results show that these cells are efficacious but do not necessarily have more persistence compared with bulk manufactured CD19-targeted CAR T cells. However, it has been suggested that the co-stimulatory domain has a stronger effect on persistence than the T cell phenotype[181]. Although there has been interest in producing CARs from other rarer subsets (such as the memory stem T cells), commercialization becomes difficult as there is a need for large-scale manufacture with good manufacturing practice (GMP)-quality reagents for cell sorting[182]. CD26^{high} CAR T cells have also been investigated because they have superior function in solid tumour models as a result of increased cytokine production (IL-17A, IFNγ, IL-2, TNF and IL-22), memory, stem-like properties (increased β-catenin and lymphoid enhancer-binding factor 1 (LEF1) expression) and trafficking (elevated CC-chemokine receptor 2 (CCR2) and CCR5 expression)[183]. γδ T cells are another potentially advantageous subset. The vast majority (95–99%) of typical CAR T cell infusion products are αβ T cells[184]. Both subsets show equivalent levels of cytotoxicity; however, γδ CAR T cells are less prone to exhaustion with lower levels of T cell immunoglobulin mucin receptor 3 (TIM3) and PD1 expression post activation. In addition, γδ CAR T cells express co-stimulation and antigen-presentation molecules (CD86 and human leukocyte antigen-DR (HLA-DR)) and have been shown to cross-present tumour antigens to other T cells in the TME[185]. Perhaps most convincingly, infiltration of γδ T cells in cancer is correlated with a favourable prognosis[186].

There are several approaches to making CAR T cell products more like a 'one-size fits all' drug (FIG. 4). One approach, which still requires an autologous cell product but leverages one vector for multiple antigen specificities, is the split, universal and programmable (SUPRA) CAR with a 'zip' system to tune the T cell response. The CAR T cells express one portion of a 'zipper' protein extracellularly, with intracellular signalling domains.



Fig. 4 | **CAR T cell subsets with increased efficacy and universal CARs with interchangeable targets.** CD26^{high} chimeric antigen receptor (CAR) T cells have increased cytokine production, a more stem-like phenotype and increased cell trafficking compared with conventional CAR T cells. CAR T cells with endogenous γδ T cell receptors (TCRs) have decreased exhaustion and increased co-stimulation compared with conventional CAR T cell products, of which 95% have αβ TCRs. Several versions of universal CARs have been published in recent years. The split, universal and programmable (SUPRA) CAR uses a 'zipper' system to interchangeably affect the CAR. The single-chain variable fragments (scFvs) can be switched to target new antigens or multiple antigens at once and the zipper binding affinity can be changed to tune the strength of the CAR signal for an appropriate response. Gating strategies can also be used by having the CD3ζ signalling domain and the co-stimulatory domain on separate molecules so that both corresponding antigens must be present to have full CAR activation. Others have pursued universal CARs through tagging tumour cells with antibodies (which are transient and can be continuously changed) conjugated to tags such as fluorescein isothiocyanate (FITC) or biotin and then developing CAR T cells against the tag to activate their cytotoxic function. CCR2, CC-chemokine receptor 2; HLA-DR, human leukocyte antigen-DR; IFNγ, interferon-γ; IL-2, interleukin 2; LEF1, lymphoid enhancer-binding factor 1; TIM3, T cell immunoglobulin mucin receptor 3.

Box 1 | **Beyond the conventional CAR T cell: CAR natural killer cells, CAR macrophages and CAR T_{reg} cells**

Natural killer (NK) cells have been pursued as the basis for development of allogeneic products owing to their intrinsic antitumour activity. NK cell-based therapy has the advantage of being cytotoxic when human leukocyte antigen (HLA) expression is downregulated, which is a relatively common tumour escape mechanism. In addition, allogeneic NK cells have been observed to have better efficacy than autologous NK cells[211,212]. A novel method involves deriving NK cells from cord blood and transducing them with an anti-CD19 chimeric antigen receptor (CAR) vector that has been engineered to ectopically produce interleukin-15 (IL-15) to increase expansion and efficacy. These cord blood CAR NK cells are cytotoxic in vitro and have persistence and antitumour effects in vivo. With respect to toxicity, these CAR NK cells have a chemically inducible caspase 9 suicide gene and can be eliminated with treatment in vivo[196]. Attempts to make CAR cells from haematopoietic stem cells have shown that CAR expression during early lymphoid development suppresses *BCL11B*, thereby suppressing T cell-associated genes. As a result, the CAR cells have NK cell-like properties, including NK cell receptor expression. These cells, termed CAR-induced killer (CARiK) cells, require a second-generation CAR design with co-stimulation to have strong anti-leukaemic effects. In a xenograft leukaemia model, allogeneic CARiK cells showed increased survival with no observed graft-versus-host disease (GvHD) despite major histocompatibility complex (MHC) mismatch[213].

Klichinsky et al.[214] recently published a description of the first CAR macrophage (CAR-M), which demonstrated antigen-specific phagocytosis and pro-inflammatory M1 polarization in vitro. CAR-Ms were also able to cross-present antigen and activate T cells. Xenograft mouse models of lung metastases and intraperitoneal carcinomatosis treated with CAR-Ms had decreased tumour burden. In humanized mice, CAR-Ms enhanced T cell antitumour responses and single-cell RNA sequencing showed induction of a pro-inflammatory tumour microenvironment[214].

CARs are also being used to redirect immunosuppressive $CD4^+CD25^+$ regulatory T cells (T_{reg} cells) as potential therapeutics in autoimmune disease and organ transplant. Several groups have shown prevention of allograft skin rejections using CAR T_{reg} cells in vivo[62,215,216]. Others have utilized CAR T_{reg} cells to ameliorate colitis[217]. However, the manufacture of CAR T_{reg} cells remains a concern for future clinical use due to difficulties purifying this cell subset from conventional T cells. Novel approaches including droplet-based sorting are currently being explored[218]. The first clinical trial for CAR T_{reg} cells was authorized in 2019 for the prevention of rejection following HLA-A2 mismatched kidney transplantation in patients with end-stage renal disease[219,220]. CTLA4, cytotoxic T lymphocyte-associated antigen 4; IFNγ, interferon-γ; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor.



CAR-NK cells
- Promising allogenic product with less GvHD
- Sufficient expansion with cord blood starting product
- Engineered ectopic IL-15 expression increases expansion and efficacy
- Require co-stimulation for significant efficacy

CAR-Ms
- CAR-induced phagocytosis of antigen-positive tumour cell
- CAR signalling results in a pro-inflammatory M1-like phenotype
- Able to cross-present and activate T cells

CAR T_{reg} cells
- Protect tissues in an antigen-dependent manner
- Secrete immunosuppressive cytokines (TGFβ, IL-10, IL-35)
- Limit local T effector cell activation through expression of molecules such as CTLA4 to outcompete for co-stimulation

Then, various protein therapeutics attached to the corresponding partner zipper can be used to change the target and signal strength of the CAR. There is also a combinatorial approach where two different zip systems are used, one with a CD3ζ signalling domain and the other with co-stimulation[187]. Other potential universal CARs include a biotin-binding immunoreceptor-based dimerizing system[188] and switch modules with neo-epitope tagging[189,190]. These CARs target a specific tag, such as fluorescein isothiocyanate (FITC) or biotin. The system then relies on a second antibody therapeutic against the target tumour antigen; this antibody is conjugated to the tag so that anti-tag CARs recognize it and are activated against the labelled tumour.

Allogeneic CARs. Third-party 'off-the-shelf' allogeneic CAR T cell therapy is highly sought after, mainly to improve standardization of the product, patient waiting times, logistics around coordinating manufacturing with patient urgency and cost[191]. The two main barriers to use of allogeneic T cell therapies are the risk of causing GvHD, which is an important safety issue, and the risk of rejection of the product, an efficacy issue. The first clinical results obtained with allogeneic gene-edited T cells were published in 2017, when two infants with B-ALL were treated with TALEN-edited TCRα-negative, CD52-negative 4-1BB-based CD19-targeted CAR T cells. Both patients achieved a complete response with minimal GvHD and went on to undergo an allogeneic

stem cell transplant, which is standard of care for this disease when it is in remission[192]. Phase I/II clinical trials using this CAR in paediatric and adult ALL are ongoing (NCT02746952 (REF.[193]) and NCT02808442 (REF.[194])). Other allogeneic CAR T cell products involve multiplexed-genome editing via CRISPR–Cas9 technology. The methodology uses lentiviral delivery of a CD19-targeted CAR and electroporation of Cas9 and single guide RNAs targeting the endogenous TCR, β_2-microglobulin and PD1 loci with the goal of reducing the risk of GvHD, rejection and exhaustion, respectively[195]. More recently, Liu et al.[196] have also leveraged cord blood-derived natural killer cells and transduced these with a CD28-based CD19-targeted CAR retroviral vector (BOX 1). Cord blood has the advantage of containing a larger proportion of natural killer cells (30% of lymphocytes compared with 10% in the peripheral blood), which lowers the risk of contaminating T cells causing GvHD. To improve natural killer cell persistence, the investigators also included a transgene for IL-15 in the construct; results from their first clinical trial demonstrated responses and sustained remissions in patients with lymphoma, and these products are now advancing in clinical development[197]. Daher et al.[198] have further improved the IL-15 design with cord blood-derived CAR natural killer cells that have a *CISH* deletion to target the cytokine-inducible SH2-containing protein, which negatively regulates IL-15 signalling. As a result, these CARs have increased aerobic glycolysis and enhanced efficacy in eliminating lymphoma xenografts in vivo.

Concluding remarks

CAR T cell research has advanced rapidly into the clinic and now back to the bench, with trial results informing new mechanisms of efficacy, toxicity and resistance, and catalysing the search for novel targets, elucidation of signalling mechanisms and application of novel technologies. Innovations in CAR design, transduction methodologies and selection of the best cell types are bound to lead to improved responses and transform the treatment of patients with many different cancer types.

Published online 22 January 2021

1. Stancovski, I. et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. *J. Immunol.* **151**, 6577–6582 (1993).
2. Eshhar, Z. et al. The T-body approach: potential for cancer immunotherapy. *Springer Semin. Immunopathol.* **18**, 199–209 (1996).
3. Hwu, P. et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. *J. Exp. Med.* **178**, 361–366 (1993).
4. Hwu, P. et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. *Cancer Res.* **55**, 3369–3373 (1995).
5. Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. *Clin. Cancer Res.* **12**, 6106–6115 (2006).
6. Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. *J. Exp. Med.* **188**, 619–626 (1998).
7. Vandenberghe, P. et al. Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. *J. Exp. Med.* **175**, 951–960 (1992).
8. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N. Engl. J. Med.* **365**, 725–733 (2011).
9. Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood* **118**, 4817–4828 (2011).
10. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci. Transl Med.* **3**, 95ra73 (2011).
11. Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci. Transl Med.* **5**, 177ra138 (2013).
12. Mullard, A. FDA approves first CAR T therapy. *Nat. Rev. Drug Discov.* **16**, 669–669 (2017).
13. Whitlow, M. et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. *Protein Eng.* **6**, 989–995 (1993).
14. Lee, L. et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. *Blood* **131**, 746–758 (2018).
15. Rajabzadeh, A., Rahbarizadeh, F., Ahmadvand, D., Kabir Salmani, M. & Hamidieh, A. A. A V_{HH}-based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells. *Cell J.* **22**, 502–513 (2021).
16. Balakrishnan, A. et al. Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors. *Clin. Cancer Res.* **25**, 7506–7516 (2019).
17. Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. *Nat. Med.* **26**, 270–280 (2020).
18. Bridgeman, J. et al. The optimal antigen response of chimeric antigen receptors harboring the CD3 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. *J. Immunol.* **184**, 6938–6949 (2010).
19. Schmidts, A. et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. *Blood Adv.* **3**, 3248–3260 (2019).
20. Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. *Nat. Biotechnol.* **20**, 70–75 (2002).
21. Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia* **18**, 676–684 (2004).
22. Pulè, M. A. et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. *Mol. Ther.* **12**, 933–941 (2005).
23. Song, D.-G. et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. *Blood* **119**, 696–706 (2012).
24. Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar T_H17/T_H1 cells. *Blood* **124**, 1070–1080 (2014).
25. Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. *Nat. Med.* **25**, 82–88 (2019).
26. Yeku, O. O., Brentjens, R. J. & Armored, C. A. R. T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. *Biochem. Soc. Trans.* **44**, 412–418 (2016).
27. Chmielewski, M. & Abken, H. CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. *Cancer Immunol. Immunother.* **61**, 1269–1277 (2012).
28. Ramello, M. C. et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. *Sci. Signal.* **12**, eaap9777 (2019).
29. Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. *Cancer Discov.* **10**, 552–567 (2020).
30. Dufva, O. et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. *Blood* **135**, 597–609 (2020).
31. Benmebarek, M. R. et al. Killing mechanisms of chimeric antigen receptor (CAR) T cells. *Int. J. Mol. Sci.* **20**, 1283 (2019).
32. Guedan, S. et al. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. *J. Clin. Invest.* **130**, 3087–3097 (2020).
33. Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. *Sci. Signal.* **11**, eaat6753 (2018).
This paper shows that CD28-based and 4-1BB-based CAR T cells utilize similar signalling molecules upon activation. However, CD28-based CAR T cells have a much larger magnitude of phosphorylation that may contribute to activation-induced cell death and early exhaustion compared with the persistence of 4-1BB-based CAR T cells, which have a more memory-like phenotype.
34. Turtle, C. J. et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of $CD8^+$ and $CD4^+$ CD19-specific chimeric antigen receptor-modified T cells. *Sci. Transl Med.* **8**, 355ra116 (2016).
35. Enblad, G. et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. *Clin. Cancer Res.* **24**, 6185–6194 (2018).
36. Levine, B. L. et al. Effects of CD28 costimulation on long-term proliferation of $CD4^+$ T cells in the absence of exogenous feeder cells. *J. Immunol.* **159**, 5921–5930 (1997).
37. Maus, M. V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. *Nat. Biotechnol.* **20**, 143–148 (2002).
38. Rubinstein, M. P. et al. IL-7 and IL-15 differentially regulate $CD8^+$ T-cell subsets during contraction of the immune response. *Blood* **112**, 3704–3712 (2008).
39. Gong, W. et al. Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. *Cancer Immunol. Immunother.* **68**, 1195–1209 (2019).
40. Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. *Cancer Immunol. Res.* **7**, 759–772 (2019).
41. Mitchell, R. S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. *PLoS Biol.* **2**, E234 (2004).
42. Schröder, A. R. W. et al. HIV-1 integration in the human genome favors active genes and local hotspots. *Cell* **110**, 521–529 (2002).
43. Kebriaei, P. et al. Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. *J. Clin. Invest.* **126**, 3363–3376 (2016).

44. Benjamin, R. et al. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19$^+$ relapsed/refractory B-cell acute lymphoblastic leukemia. *Blood* **132**, 896 (2018).
45. Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. *Science* **367**, eaba7365 (2020).
46. Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat. Med.* **24**, 563–571 (2018).
This paper shows that CAR T cell products with a less exhausted phenotype have more favourable clinical outcomes.
47. Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature* **558**, 307–312 (2018).
This paper shows that a single CAR T cell is capable of creating a long-lasting, durable antitumour response.
48. Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. *Cell* **175**, 1958–1971.e15 (2018).
49. Nobles, C. L. et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. *J. Clin. Invest.* **130**, 673–685 (2020).
50. van Bruggen, J. A. C. et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8$^+$ T cells and impede CAR T-cell efficacy. *Blood* **134**, 44–58 (2019).
51. Garfall, A. L. et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. *Blood Adv.* **3**, 2812–2815 (2019).
52. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N. Engl. J. Med.* **377**, 2531–2544 (2017).
53. Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N. Engl. J. Med.* **378**, 439–448 (2018).
54. van der Stegen, S. J. C., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. *Nat. Rev. Drug Discov.* **14**, 499–509 (2015).
55. Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci. Transl Med.* **7**, 303ra139 (2015).
56. Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. *Immunity* **44**, 712 (2016).
57. Zhang, H. et al. 4-1BB is superior to CD28 costimulation for generating CD8$^+$ cytotoxic lymphocytes for adoptive immunotherapy. *J. Immunol.* **179**, 4910–4918 (2007).
58. Philipson, B. I. et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. *Sci. Signal.* **13**, eaay8248 (2020).
59. Li, G. et al. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. *JCI Insight* **3**, e121322 (2018).
60. Boroughs, A. C. et al. A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq. *Mol. Ther.* **28**, 2577–2592 (2020).
61. Li, W. et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. *Immunity* **53**, 456–470.e6 (2020).
62. Boroughs, A. C. et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. *JCI Insight* **4**, e126194 (2019).
63. Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI Insight* **3**, e96976 (2018).
64. Youngblood, B., Davis, C. W. & Ahmed, R. Making memories that last a lifetime: heritable functions of self-renewing memory CD8 T cells. *Int. Immunol.* **22**, 797–803 (2010).
65. Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. *Nat. Rev. Immunol.* **15**, 486–499 (2015).
66. Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. *Mol. Ther.* **25**, 2189–2201 (2017).
This paper shows that antigen density on target cells plays a large role in CAR T cell efficacy.
67. Singh, N. et al. Single chain variable fragment linker length regulates CAR biology and T cell efficacy. *Blood* **134**, 247–247 (2019).
This paper shows that linker length alone can affect CAR T cell efficacy.
68. Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. *Mol. Ther. Oncolytics* **11**, 127–137 (2018).
69. Majzner, R. G. et al. Tuning the antigen density requirement for CAR T cell activity. *Cancer Discov.* **10**, 702–723 (2020).
70. Stoiber, S. et al. Limitations in the design of chimeric antigen receptors for cancer therapy. *Cells* **8**, 472 (2019).
71. Alabanza, L. et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. *Mol. Ther.* **25**, 2452–2465 (2017).
72. Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. *Nature* **543**, 113–117 (2017).
73. Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. *Clin. Cancer Res.* **19**, 3153–3164 (2013).
74. Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. *Cancer Immunol. Res.* **3**, 125–135 (2015).
75. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03620058 (2018).
76. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02650414 (2016).
77. Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scfvs and antigens. *J. Immunother.* **28**, 203–211 (2005).
78. James, S. E. et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. *J. Immunol.* **180**, 7028–7038 (2008).
79. Xu, Y. et al. A novel antibody–TCR (AbTCR) platform combines Fab-based antigen recognition with γ/δ-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. *Cell Discov.* **4**, 62 (2018).
80. Wu, W. et al. Multiple signaling roles of CD3ε and its application in CAR-T cell therapy. *Cell* **182**, 855–871. e23 (2020).
81. Hartl, F. A. et al. Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function. *Nat. Immunol.* **21**, 902–913 (2020).
82. Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. *Nat. Rev. Clin. Oncol.* **15**, 47–62 (2018).
83. Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood* **130**, 2295–2306 (2017).
84. Gust, J., Taraseviciute, A. & Turtle, C. J. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. *CNS Drugs* **32**, 1091–1101 (2018).
85. Riddell, S. R. Adrenaline fuels a cytokine storm. *Nature* **564**, 194–196 (2018).
86. Staedtke, V. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. *Nature* **564**, 273–277 (2018).
87. Gust, J. et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov.* **7**, 1404–1419 (2017).
88. Mueller, K. T. et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. *Clin. Cancer Res.* **24**, 6175–6184 (2018).
89. Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. *Cancer Discov.* **8**, 958–971 (2018).
This paper shows that neurotoxicity is correlated with levels of pro-inflammatory cytokines in the CSF.
90. Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. *Cell* **183**, 126–142.e17 (2020).
91. Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. *Nat. Med.* **24**, 731–738 (2018).
This paper shows that interfering with IL-1 signalling can have a large affect, mitigating CRS and neurotoxicity.
92. Taraseviciute, A. et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. *Cancer Discov.* **8**, 750–763 (2018).
93. Pennell, C. A. et al. Human CD19-targeted mouse T cells induce B cell aplasia and toxicity in human CD19 transgenic mice. *Mol. Ther.* **26**, 1423–1434 (2018).
94. Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. *Nat. Med.* **24**, 739–748 (2018).
95. Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. *Blood* **133**, 697–709 (2019).
96. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT04150913 (2019).
97. Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. *Sci. Transl Med.* **11**, eaau5907 (2019).
98. Casucci, M. et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene. *Front. Immunol.* **9**, 507 (2018).
99. Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. *Blood Adv.* **3**, 711–717 (2019).
100. Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. *Nat. Med.* **24**, 1504–1506 (2018).
This paper shows that mutations and selective pressure can lead to loss of target antigen on tumours, leading to antigen-negative relapse.
101. Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nat. Med.* **24**, 1499–1503 (2018).
This paper shows that tumour cell-based contamination during the manufacturing process can lead to relapse due to accidental transduction with a CAR, masking the cell surface antigen.
102. Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. *Nature* **568**, 112–116 (2019).
103. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N. Engl. J. Med.* **371**, 1507–1517 (2014).
104. Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H. & O'Rourke, D. M. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. *Neuro-oncology* **20**, 1429–1438 (2018).
105. Zhang, W.-y et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. *Signal. Transduct. Target. Ther.* **1**, 16002 (2016).
106. Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. *Nat. Med.* **24**, 20–28 (2018).
107. Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. *Cancer Cell* **35**, 473–488.e6 (2019).
108. Pont, M. J. et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. *Blood* **134**, 1585–1597 (2019).
109. Ramakrishna, S. et al. Modulation of target antigen density improves CAR T-cell functionality and persistence. *Clin. Cancer Res.* **25**, 5329–5341 (2019).
110. Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. *Cancer Res.* **75**, 3596–3607 (2015).
111. Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. *Nat. Rev. Immunol.* **18**, 153–167 (2018).
112. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. *Curr. Opin. Immunol.* **24**, 207–212 (2012).
113. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med.* **366**, 2443–2454 (2012).
114. Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. *J. Clin. Invest.* **126**, 3130–3144 (2016).
This paper shows that exhausted CAR T cells may be revived through checkpoint blockade.
115. Chong, E. A. et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. *Blood* **132**, 4198 (2018).

116. Hirayama, A. V. et al. Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Blood* **132**, 1680 (2018).
117. Jacobson, C. A. et al. End of phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. *Biol. Blood Marrow Transplant.* **25**, S173 (2019).
118. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03310619 (2017).
119. Chong, E. A. et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood* **129**, 1039–1041 (2017).
120. Suarez, E. R. et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. *Oncotarget* **7**, 34341–34355 (2016).
121. Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. *Nat. Biotechnol.* **36**, 847–856 (2018).
122. Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. *N. Engl. J. Med.* **378**, 158–168 (2018).
123. Rupp, L. J. et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. *Sci. Rep.* **7**, 737 (2017).
124. Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. *Cancer Discov.* **7**, 1238–1247 (2017).
125. Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. *Nature* **576**, 293–300 (2019).
126. Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. *Nat. Biotechnol.* **36**, 346–351 (2018).
127. Yeku, O. O. et al. T cells enhance antitumor efficacy and overcome the tumor microenvironment. *Sci. Rep.* **7**, 10541 (2017).
128. Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. *Cell Rep.* **23**, 2130–2141 (2018).
129. Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. *Nat. Biotechnol.* **38**, 448–459 (2020).
130. Kloss, C. C. et al. Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. *Mol. Ther.* **26**, 1855–1866 (2018).
131. Narayan, V. et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. *J. Clin. Oncol.* **38**, TPS269 (2020).
132. Tang, N. et al. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. *JCI Insight* **5**, e133977 (2020).
133. O'Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci. Transl Med.* **9**, eaaa0984 (2017).
134. Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. *Nat. Biotechnol.* **37**, 1049–1058 (2019).
135. Wing, A. et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. *Cancer Immunol. Res.* **6**, 605–616 (2018).
136. Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. *Science* **365**, 162–168 (2019).
137. Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N. Engl. J. Med.* **380**, 1726–1737 (2019).
138. Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *J. Clin. Invest.* **129**, 2210–2221 (2019).
139. Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. *Blood* **128**, 1688–1700 (2016).
140. Ma, T., Shi, J. & Liu, H. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. *Ann. Hematol.* **98**, 813–822 (2019).
141. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03287804 (2017).
142. Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. *Sci. Transl Med.* **11**, eaau7746 (2019).
143. Gagelmann, N. et al. Development of CAR-T cell therapies for multiple myeloma. *Leukemia* **34**, 2317–2332 (2020).
144. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02982941 (2016).
145. Desantes, K. et al. A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors. *J. Clin. Oncol.* **35**, TPS2596 (2017).
146. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02381314 (2015).
147. Urba, W. et al. A phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer. *J. Immunother. Cancer* **3**, P176 (2015).
148. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03406949 (2018).
149. Shankar, S. et al. A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 × CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors. *J. Clin. Oncol.* **36**, TPS2601 (2018).
150. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02628535 (2015).
151. Tolcher, A. W. et al. Phase 1, first-in-human, open label, dose escalation study of MGD009, a humanized B7-H3 × CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature. *J. Clin. Oncol.* **34**, TPS3105 (2016).
152. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03729596 (2018).
153. Scribner, J. A. et al. Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer [abstract 820]. *American Association for Cancer Research Annual Meeting, 2018.* (American Association for Cancer Research, 2018).
154. Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. *Clin. Cancer Res.* **25**, 2560–2574 (2019).
155. He, Y. et al. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. *JCI Insight* **4**, e135306 (2019).
156. Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-targeted CARs: driving T cells to solid tumors. *Cancer Discov.* **6**, 133–146 (2016).
157. Adusumilli P. S. et al. A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR-T cells [abstract CT036]. *2019 AACR Annual Meeting* (American Association for Cancer Research, 2019).
158. Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. *Mol. Ther.* **27**, 1919–1929 (2019).
159. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03907852 (2019).
160. Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. *Nat. Commun.* **10**, 2087 (2019).
161. Brown, C. E. et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor $CD8^+$ T cells in patients with recurrent glioblastoma. *Clin. Cancer Res.* **21**, 4062–4072 (2015).
162. Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. *JAMA Oncol.* **3**, 1094–1101 (2017).
163. Wang, D.-r. et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. *Sci. Transl Med.* **12**, eaaw2672 (2020).
164. Richards, R. M., Sotillo, E. & Majzner, R. G. CAR T cell therapy for neuroblastoma. *Front. Immunol.* **9**, 2380 (2018).
165. Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M$^+$ diffuse midline gliomas. *Nat. Med.* **24**, 572–579 (2018).
166. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03294954 (2017).
167. Heczey, A. et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. *Nat. Med.* **26**, 1686–1690 (2020).
168. Bosse, K. R. et al. Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. *Cancer Cell* **32**, 295–309. e12 (2017).
169. Macdonald, G. Cell and Gene Therapy https://www.pmlive.com/pharma_intelligence/Cell_and_gene_therapy_1278537?SQ_DESIGN_NAME=2 (PMLiVE, 2019).
170. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT00968760 (2009).
171. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT01497184 (2011).
172. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT03389035 (2018).
173. Magnani, C. F. et al. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. *J. Clin. Invest.* **130**, 6021–6033 (2020).
174. Barnett, B. E. et al. piggyBacTM-produced CAR-T cells exhibit stem-cell memory phenotype. *Blood* **128**, 2167 (2016).
175. Poseida Therapeutics. *Pipeline* https://poseida.com/pipeline/ (2020).
176. Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. *Nature* **559**, 405–409 (2018).
177. Schober, K. et al. Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. *Nat. Biomed. Eng.* **3**, 974–984 (2019).
178. Silva, D. A. et al. De novo design of potent and selective mimics of IL-2 and IL-15. *Nature* **565**, 186–191 (2019).
179. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT01318317 (2011).
180. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT01815749 (2013).
181. Wang, X. et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. *Blood* **127**, 2980–2990 (2016).
182. Murray, C., Pao, E., Jann, A., Park, D. E. & Di Carlo, D. Continuous and quantitative purification of T-cell subsets for cell therapy manufacturing using magnetic ratcheting cytometry. *SLAS Technol.* **23**, 326–337 (2018).
183. Bailey, S. R. et al. Human $CD26^{high}$ T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. *Nat. Commun.* **8**, 1961 (2017).
184. Deniger, D. C. et al. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. *Mol. Ther.* **21**, 638–647 (2013).
185. Capsomidis, A. et al. Chimeric antigen receptor-engineered human γδ T cells: enhanced cytotoxicity with retention of cross presentation. *Mol. Ther.* **26**, 354–365 (2018).
186. Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat. Med.* **21**, 938–945 (2015).
187. Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. *Cell* **173**, 1426–1438.e11 (2018).
188. Lohmueller, J. J., Ham, J. D., Kvorjak, M. & Finn, O. J. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. *OncoImmunology* **7**, e1368604 (2018).
189. Ma, J. S. Y. et al. Versatile strategy for controlling the specificity and activity of engineered T cells. *Proc. Natl Acad. Sci. USA* **113**, E450–E458 (2016).
190. Cartellieri, M. et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. *Blood Cancer J.* **6**, e458 (2016).
191. Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. *Nat. Rev. Drug Discov.* **19**, 185–199 (2020).
192. Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Sci. Transl Med.* **9**, eaaj2013 (2017).
193. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02746952 (2016).
194. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02808442 (2016).
195. Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. *Clin. Cancer Res.* **23**, 2255–2266 (2017).
196. Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. *Leukemia* **32**, 520–531 (2018).

197. Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. *N. Engl. J. Med.* **382**, 545–553 (2020).
198. Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. *Blood* https://doi.org/10.1182/blood.2020007748 (2020).
199. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02435849 (2015).
200. Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. *Lancet Oncol.* **20**, 31–42 (2019).
201. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02348216 (2015).
202. Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. *N. Engl. J. Med.* **377**, 2545–2554 (2017).
203. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02030834 (2014).
204. Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *N. Engl. J. Med.* **382**, 1331–1342 (2020).
205. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02601313 (2015).
206. Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N. Engl. J. Med.* **378**, 449–459 (2018).
207. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT01044069 (2010).
208. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02315612 (2014).
209. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02658929 (2016).
210. US National Library of Medicine. *ClinicalTrials.gov* https://ClinicalTrials.gov/show/NCT02546167 (2015).
211. Iliopoulou, E. G. et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. *Cancer Immunol. Immunother.* **59**, 1781–1789 (2010).
212. Mehta, R. S. & Rezvani, K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. *Front. Immunol.* **9**, 283 (2018).
213. Maluski, M. et al. Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development. *J. Clin. Invest.* **129**, 5108–5122 (2019).
214. Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nat. Biotechnol.* **38**, 947–953 (2020).
215. Noyan, F. et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. *Am. J. Transpl.* **17**, 917–930 (2017).
216. Boardman, D. A. et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. *Am. J. Transpl.* **17**, 931–943 (2017).
217. Blat, D., Zigmond, E., Alteber, Z., Waks, T. & Eshhar, Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. *Mol. Ther.* **22**, 1018–1028 (2014).
218. Fritsche, E., Volk, H.-D., Reinke, P. & Abou-El-Enein, M. Toward an optimized process for clinical manufacturing of CAR-T_{reg} cell therapy. *Trends Biotechnol.* **38**, 1099–1112 (2020).
219. Dawson, N. A. J. et al. Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells. *JCI Insight* **4**, e123672 (2019).
220. European Medicines Agency *EU Clinical Trials Register* https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001730-34/NL (2019).

Acknowledgements
M.V.M. is funded by the National Institutes of Health (NIH) (R01 CA238268, R01 CA252940), the Leukemia and Lymphoma Society, Stand Up to Cancer and the Damon Runyon Cancer Research Foundation. R.C.L. has been funded by NIH T32 GM007306 and is currently funded by NIH T32 AI007529.

Author contributions
M.V.M. and R.C.L. researched the data for the article and selected the content, and otherwise contributed equally to writing the article and to review and/or editing of the manuscript before submission.

Competing interests
M.V.M. and R.C.L. have intellectual property on certain chimeric antigen receptor (CAR) T cells and antibodies (not yet licensed). M.V.M. receives consulting income from several industry sponsors that market CAR T cell therapies, serves on several scientific advisory boards and has equity in TCR2 and Century Therapeutics.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2021